Literature DB >> 2584296

Routine measurement of plasma catecholamines in clinical pharmacology by high-performance liquid chromatography with electrochemical detection.

I Meineke1, E Stüwe, E M Henne, G Rusteberg, E Brendel, C De Mey.   

Abstract

A method for the simultaneous determination of epinephrine, norepinephrine and dopamine in human plasma is described, which combines the advantages of liquid-liquid extraction sample preparation, high-performance liquid chromatography on weak cation-exchange stationary phases and dual-electrode coulometric detection. The limits of quantification are less than 5 pg/ml (at a signal-to-noise ratio greater than 5) for each analyte. The influence of various experimental parameters (e.g., composition of the mobile phase, pretreatment of the assay buffer, components of the re-extraction system) on the performance of the assay is reported in detail. A number of applications are presented, which demonstrate the quality of the data obtained in terms of sensitivity, reproducibility and significance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584296     DOI: 10.1016/s0378-4347(00)82735-8

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.

Authors:  C de Mey; D Enterling; I Meineke; S Yeulet
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

2.  Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies.

Authors:  C De Mey; K Breithaupt-Grögler; J Schloos; D Palm; G G Belz
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

3.  Cardiovascular effects of eating, atenolol and their interaction: beta1-adrenergic modulation does not play a predominant role in the genesis of postprandial effects.

Authors:  C De Mey; D Enterling; I Meineke
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.